Previous Article | Next Article ![]()
Infection and Immunity, February 1999, p. 562-567, Vol. 67, No. 2
Division of Bacteriology, United States Army
Medical Research Institute of Infectious Diseases, Fort Detrick,
Frederick, Maryland 21701-5011
Received 6 July 1998/Returned for modification 10 August
1998/Accepted 4 November 1998
The protective efficacy of several live, recombinant anthrax
vaccines given in a single-dose regimen was assessed with Hartley guinea pigs. These live vaccines were created by transforming
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Vaccination against Anthrax with Attenuated Recombinant
Strains of Bacillus anthracis That Produce
Protective Antigen
and
ANR
and
Sterne, two nonencapsulated, nontoxinogenic
strains of Bacillus anthracis, with four different
recombinant plasmids that express the anthrax protective antigen
(PA) protein to various degrees. This enabled us to assess the effect
of the chromosomal background of the strain, as well as the amount of
PA produced, on protective efficacy. There were no significant
strain-related effects on PA production in vitro, plasmid stability in
vivo, survival of the immunizing strain in the host, or protective
efficacy of the immunizing infection. The protective efficacy of the
live, recombinant anthrax vaccine strains correlated with the anti-PA antibody titers they elicited in vivo and the level of PA they produced
in vitro.
*
Corresponding author. Mailing address: USAMRIID, 1425 Porter Street, Fort Detrick, MD 21702-5011. Phone: (301) 619-7341. Fax: (301) 619-2152. E-mail: friedlan{at}ncifcrf.gov.
Present address: Department of Microbiology, State University of
New York, Buffalo, NY 14214-3005.
This article has been cited by other articles:
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|